Register for email alerts and news feeds:
This journal | BMJ Group
rss
Molecular Pathology 2003;56:239; doi:10.1136/mp.56.4.239
Copyright © 2003 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.
Molecular Pathology 2003;56:239
© 2003 BMJ Publishing Group Ltd. & Association of Clinical Pathologists

ECHO

Protein kinase regulates IL16 transcription in arthritis

The first 150 words of the full text of this article appear below.

Molecular researchers have suggested that pathways dependent on protein kinase C may regulate transcription of interleukin 16 (IL16), a proinflammatory cytokine abundant in arthritic joints.

They compared the effect of various chemical agents on steady state (IL16) mRNA transcripts in growing synovial fibroblasts from six patients with rheumatoid arthritis (RA) and three with osteoarthritis (OA). The reverse transcriptase PCR method they used enabled them to obtain results that were semiquantitative.

Early passage synovial fibroblasts from patients with RA or OA transcribed IL16 mRNA when incubated with growing medium without additives. Protein kinase inhibitor staurosporine enhanced IL16 steady state mRNA in both types of synovial fibroblasts and specific protein kinase C activator phorbol-12-myristate-13-acetate reduced transcription. Other agents—the calcium ionophore ionomycin, protein kinase A stimulator cyclic AMP, and G protein activator MAS-7—gave minor, variable responses. Phosphatase inhibitor okadaic acid and protein kinase inhibitor H-7 dihydrochloride reduced mRNA transcripts, maybe because of their . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Pathology jobs

Pathology jobs